Tetracycline antibiotics, discovered in the 1940s, inhibit protein synthesis by preventing the attachment of aminoacyl-tRNA to the ribosomal A site. They are broad-spectrum agents effective against gram-positive and gram-negative bacteria, atypical organisms, and protozoan parasites. Widely used in human and veterinary medicine, they are also used prophylactically for malaria and as growth promoters in animal feeds. However, microbial resistance has limited their effectiveness. The emergence of resistance is attributed to their clinical use, and concerns about their use as growth promoters have increased. Understanding resistance mechanisms is crucial for developing new tetracyclines and inhibitors to restore their activity. Tetracyclines include first-generation (1948–1963), second-generation (1965–1972), and third-generation (glycylcyclines) compounds. The structure-activity relationships of tetracyclines involve maintaining a linear fused tetracyclic nucleus, specific stereochemical configurations, and a keto-enol system. Glycylcyclines, like minocycline, have a 9-glycylamido substituent and show improved activity against resistant organisms. Tetracyclines inhibit protein synthesis by binding to the ribosome, preventing aminoacyl-tRNA from attaching. They are taken up via membrane systems and bind to the ribosome, causing reversible bacteriostatic effects. Resistance mechanisms include efflux pumps, ribosomal protection proteins, and enzymatic inactivation. Efflux proteins are the best studied, belonging to the major facilitator superfamily. Ribosomal protection proteins, like Tet(M) and Tet(O), protect ribosomes from tetracycline by altering ribosomal conformation. Enzymatic inactivation, such as the Tet(X) gene, modifies tetracycline. Resistance genes are distributed among bacteria, with some genes found in both gram-positive and gram-negative species. The regulation of resistance genes involves repressor proteins that bind to DNA operators, and their expression is induced by tetracycline. Efflux genes are regulated by tetracycline, with the repressor protein binding to DNA operators in the absence of tetracycline. In the presence of tetracycline, the repressor protein undergoes conformational changes, allowing transcription of efflux and repressor genes. The study highlights the importance of understanding tetracycline resistance mechanisms to develop new antibiotics and strategies to combat resistance. The emergence of resistance has led to the discovery of glycylcyclines and the need for inhibitors to restore tetracycline activity. The distribution and regulation of resistance genes are critical for managing the continued use of tetracyclines in clinical and veterinary settings.Tetracycline antibiotics, discovered in the 1940s, inhibit protein synthesis by preventing the attachment of aminoacyl-tRNA to the ribosomal A site. They are broad-spectrum agents effective against gram-positive and gram-negative bacteria, atypical organisms, and protozoan parasites. Widely used in human and veterinary medicine, they are also used prophylactically for malaria and as growth promoters in animal feeds. However, microbial resistance has limited their effectiveness. The emergence of resistance is attributed to their clinical use, and concerns about their use as growth promoters have increased. Understanding resistance mechanisms is crucial for developing new tetracyclines and inhibitors to restore their activity. Tetracyclines include first-generation (1948–1963), second-generation (1965–1972), and third-generation (glycylcyclines) compounds. The structure-activity relationships of tetracyclines involve maintaining a linear fused tetracyclic nucleus, specific stereochemical configurations, and a keto-enol system. Glycylcyclines, like minocycline, have a 9-glycylamido substituent and show improved activity against resistant organisms. Tetracyclines inhibit protein synthesis by binding to the ribosome, preventing aminoacyl-tRNA from attaching. They are taken up via membrane systems and bind to the ribosome, causing reversible bacteriostatic effects. Resistance mechanisms include efflux pumps, ribosomal protection proteins, and enzymatic inactivation. Efflux proteins are the best studied, belonging to the major facilitator superfamily. Ribosomal protection proteins, like Tet(M) and Tet(O), protect ribosomes from tetracycline by altering ribosomal conformation. Enzymatic inactivation, such as the Tet(X) gene, modifies tetracycline. Resistance genes are distributed among bacteria, with some genes found in both gram-positive and gram-negative species. The regulation of resistance genes involves repressor proteins that bind to DNA operators, and their expression is induced by tetracycline. Efflux genes are regulated by tetracycline, with the repressor protein binding to DNA operators in the absence of tetracycline. In the presence of tetracycline, the repressor protein undergoes conformational changes, allowing transcription of efflux and repressor genes. The study highlights the importance of understanding tetracycline resistance mechanisms to develop new antibiotics and strategies to combat resistance. The emergence of resistance has led to the discovery of glycylcyclines and the need for inhibitors to restore tetracycline activity. The distribution and regulation of resistance genes are critical for managing the continued use of tetracyclines in clinical and veterinary settings.